NCT02100813

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 220 (actual)
• Sponsor: LEO Pharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To identify the Maximum Tolerated Dose levels of LEO 43204 after once daily treatment for two consecutive days and to evaluate efficacy of LEO 43204 in two doses after once daily treatment for two consecutive days compared to vehicle

Conditions

• Actinic Keratosis

Interventions

Type	Name	Description
DRUG	LEO 43204
DRUG	Placebo

Timeline

• Start date: 2014-05-01
• Primary completion: 2015-03-01
• Completion: 2015-03-01
• First posted: 2014-04-01
• Last updated: 2025-03-06
• Results posted: 2019-02-18

Locations

1 site across 1 country: United States